Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Metformin may attenuate osteoporosis risk in diabetic patients with carcinoma in situ

Key clinical point: Diabetic patients with carcinoma in situ (CIS) under metformin therapy presented a lower osteoporosis rate vs. those who were not receiving metformin.

Major finding: The risk of osteoporosis was lower in diabetic patients with CIS who were receiving metformin therapy vs. those who were not receiving metformin (adjusted hazard ratio, 0.82; P = .022).

Study details: This retrospective matched-cohort study included 7,827 diabetic patients with CIS treated with metformin and 23,481 matched controls with no metformin therapy.

Disclosures: The study was funded by the Tri-Service General Hospital Research Foundation, the National Defense Medical Center, Ministry of National Defense-Medical Affairs Bureau, and the Teh-Tzer Study Group for Human Medical Research Foundation. The authors declared no conflicts of interest.

Citation:

Lu CH et al. J Clin Med. 2020 Sep 2. doi: 10.3390/jcm9092839.